eCite Digital Repository

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease

Citation

Moore, OA and Proudman, SM and Goh, N and Corte, TJ and Rouse, H and Hennessy, O and Morrisroe, K and Thakkar, V and Sahhar, J and Roddy, J and Youssef, P and Gabbay, E and Nash, P and Zochling, J and Stevens, W and Nikpour, M, Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease, Clinical and Experimental Rheumatology, 33, (4 Suppl 91) pp. S111-S116. ISSN 0392-856X (2015) [Refereed Article]


Preview
PDF
Restricted - Request a copy
242Kb
  

Copyright Statement

Copyright 2015 Clinical and Experimental Rheumatology

Official URL: http://www.clinexprheumatol.org/abstract.asp?a=875...

Abstract

Objective: Clinically meaningful change in systemic sclerosis (SSc) related interstitial lung (SSc-ILD) disease is unknown. The aim of this study was to quantify change in pulmonary function as a predictor of outcome in SSc-ILD.

Methods: All patients had SSc-ILD defined by HRCT chest. All PFTs during follow-up, including FVC (L), DLCO (ml/min/mmHg) and KCO (DLCO/alveolar volume ratio; DLCO/VA) (ml/min/mmHg/L) were retrieved. The rate of change over the first four years, and percentage change in the first year of follow-up were used in ROC curve analysis to determine the best cut-off points to predict adverse outcome (home oxygen, lung transplantation, or death).

Results: Among 264 patients, there were 49 events (38 deaths, 10 supplemental oxygen, one lung transplant) over a mean (± SD) follow-up of 3.0 (± 1.7) years. The rates of decline over time and percentage change over one year in each of FVC, DLCO and KCO were predictive of adverse outcome. Stable PFTs over four years gave the optimal negative predictive values (NPVs) of 88-96%. The best sensitivity-specificity trade-off was a decline in FVC of 10% and in DLCO and KCO of 15% with NPVs of 92-93%.

Conclusion: The course that SSc-ILD takes is evident within the first 1-4 years of follow up. Patients who have no decline in PFTs over 4 years have better outcomes. A decline within one year in DLCO or KCO of 15% or more is a poor prognostic factor, and identifies patients who should be monitored more closely and considered for therapy.

Item Details

Item Type:Refereed Article
Keywords:scleroderma, systemic sclerosis, interstitial lung disease, pulmonary function, prognosis
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Rheumatology and Arthritis
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Zochling, J (Dr Jane Zochling)
ID Code:103482
Year Published:2015
Web of Science® Times Cited:11
Deposited By:Menzies Institute for Medical Research
Deposited On:2015-10-13
Last Modified:2017-11-01
Downloads:0

Repository Staff Only: item control page